PDE4B Selective Pyrazolo[5,1-b][1,3]oxazine Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors often cause gastrointestinal side effects such as nausea, emesis, and diarrhea, primarily associated with inhibition of the PDE4D isoform, and there is a need for selective PDE4 inhibitors with enhanced binding affinity for the PDE4B isoform to treat central nervous system, metabolic, autoimmune, and inflammatory diseases with reduced side effects.
Innovation Solution
Development of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine compounds that selectively inhibit the PDE4B isoform, offering improved binding affinity over PDE4D, thereby reducing gastrointestinal side effects and providing therapeutic benefits for various diseases and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE4 inhibitors are used to treat diseases, then therapeutic benefits are achieved, but gastrointestinal side effects occur
Solution Approach 1:
The invention segments the PDE4 enzyme family into distinct isoforms (PDE4A, PDE4B, PDE4C, PDE4D) and develops inhibitors that selectively target specific isoforms. The compounds of Formula I are designed to preferentially inhibit PDE4B while sparing PDE4D, thereby achieving therapeutic benefits through PDE4B inhibition while avoiding the gastrointestinal side effects associated with PDE4D inhibition.
Solution Approach 2:
The invention applies local quality by creating isoform-specific inhibition profiles. The compounds exhibit different binding affinities for different PDE4 isoforms, with enhanced selectivity for PDE4B. This localized selectivity allows therapeutic action in target tissues expressing PDE4B while minimizing adverse effects in gastrointestinal tissues where PDE4D is predominantly expressed.
2Adaptability or versatility
If non-selective PDE4 inhibitors are used, then broad therapeutic effects are achieved, but selectivity for PDE4B isoform is reduced
Solution Approach 1:
The invention divides the non-selective PDE4 inhibition approach into isoform-specific inhibition. The compounds of Formula I are structurally designed to recognize and bind preferentially to the PDE4B isoform through specific molecular interactions, while exhibiting reduced affinity for other isoforms. This segmentation maintains therapeutic versatility by enabling targeted intervention in PDE4B-mediated pathologies.
Solution Approach 2:
The invention employs parameter changes by modifying the chemical structure of PDE4 inhibitors to optimize binding affinity and selectivity. The compounds of Formula I incorporate specific structural features (substituents R1-R6 at defined positions) that tune the molecular parameters to achieve enhanced selectivity for PDE4B, transforming a non-selective inhibitor into an isoform-selective agent.
3Reliability
If PDE4D isoform is inhibited, then anti-inflammatory effects are achieved, but gastrointestinal side effects increase
Solution Approach 1:
The invention extracts the anti-inflammatory therapeutic effect from the harmful gastrointestinal side effects by selectively inhibiting PDE4B, the isoform responsible for therapeutic benefits, while avoiding inhibition of PDE4D, the isoform associated with gastrointestinal adverse effects. This extraction separates the desired therapeutic action from the unwanted side effects.
Solution Approach 2:
The invention applies local quality by creating differential inhibition across PDE4 isoforms. The compounds exhibit localized selectivity for PDE4B over PDE4D, enabling anti-inflammatory effects through PDE4B inhibition in immune and inflammatory cells while sparing PDE4D in gastrointestinal tissues, thus achieving tissue-specific therapeutic action with minimal systemic side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat central nervous system, metabolic, autoimmune, and inflammatory diseases with reduced gastrointestinal side effects, demonstrating enhanced binding affinity for the PDE4B isoform while minimizing activity on the PDE4D isoform, thus offering a more targeted therapeutic approach.
Implementation Method 1
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine compounds of Formula I, which are inhibitors of PDE4 isozymes, especially with a binding affinity for the PDE4B isoform
Data Source
AI summary
The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.